Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.
Article Date
October 1, 2024
This article is featured on another website.
Go to article
September 23, 2026
Chime Biologics and Magic Mirror Biotech Enter Strategic Partnership to Advance AI-Enabled Intelligent Manufacturing Across the Biologics Lifecycle
September 23, 2026
Chime Biologics and Magic Mirror Biotech Enter Strategic Partnership to Advance AI-Enabled Intelligent Manufacturing Across the Biologics Lifecycle
September 1, 2026
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
HiRO and Differentia have signed a Memorandum of Understanding establishing a framework for joint development…
September 1, 2026
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
HiRO and Differentia have signed a Memorandum of Understanding establishing a framework for joint development…